Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma-Reference-Cited by-同舟云学术

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

Published:2014-10 Issue:10 Volume:4 Page:e250-e250
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Silvennoinen R,Lundan T,Kairisto V,Pelliniemi T-T,Putkonen M,Anttila P,Huotari V,Mäntymaa P,Siitonen S,Uotila L,Penttilä T-L,Juvonen V,Selander T,Remes K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201469.pdf

Reference29 articles.

1. Van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M . Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399–1406.

2. Harousseau JL, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139–3146.

3. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

4. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691–4695.

5. Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A . Minimal residual disease in myeloma: are we there yet?. Biol Blood Marrow Transplant 2012; 18: 1790–1799.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group;Cancers;2024-02-29

2. MRD in multiple myeloma: does CR really matter?;Blood;2022-12-08

3. Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside;Experimental Hematology & Oncology;2022-09-03

4. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New;Cancers;2021-08-27

5. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators;The Journal of Molecular Diagnostics;2021-05